Board of directors
CSO, Founder & Chairman of the Board at Aurealis Therapeutics.
Iain brings to the company considerable experience in the Pharmaceutical and Biotech industries in both executive and non-executive roles. Most recently he served as CEO of NOXXON Pharma AG in Berlin. Prior to that, Iain was CEO of Novexel SA in Paris from its creation as the anti-infective spin out from Sanofi-Aventis in 2004 until its sale in 2009. Previously, he held a variety of management roles including a senior position with Vertex Pharmaceuticals where he was responsible for business development activities and for creating the European subsidiary. In the past he also worked for both Cilag AG (a division of Johnson and Johnson) and Biogen SA in Switzerland.
Iain holds a Bachelor of Science in Physiology from the University of St. Andrews, Scotland, and currently serves as a non-executive director of Synairgen Plc and a member of the advisory board of Allecra Therapeutics.
Nora has exceptionally broad experience and demonstrated quick learning capabilities across industries, from medical devices, pharmaceuticals and molecular diagnostics to complex hospital projects, corporate governance and venture capital business. Nora is currently the Head of Health Industry at Finpro, a public organization helping Finnish SMEs go international, encouraging foreign direct investment in Finland and promoting travel to Finland.
She is a board director at Aurealis Therapeutics and Pharmatest Services Ltd. In her extensive and versatile international career she has hold senior executive positions at Inveni Secondaries Management, Ipsat Therapies Ltd, Jurilab Ltd, Medex International, Baxter Biotech, Haemonetics and Instrumentarium (acquired by GE Healthcare). Nora has an MSc in electromedical engineering from St. Petersburg Electrotechnical University “LETI” and an MBA from IMD Geneva.
Silvio has held multiple senior positions in the pharmaceutical industry during the last 20 years. With his origin in pharmaceutical manufacturing, he built a corporate-wide GMP-quality assurance infrastructure as Head of Quality Assurance, and was responsible for product release as a Qualified Person in a medium-sized Swiss pharmaceutical company.
He was later elected to the position of Technical Director and served on the Corporate Management Team, ultimately joining the Board of Directors and becoming co-owner of the privately-held 450 employee company. Prior to the successful sale of the company, he served as a CEO and was responsible for its foreign subsidiaries. He is an active investor, consultant and board member of several life science start-up companies. Dr. Inderbitzin studied Pharmacy at the University of Berne, he holds a PhD in Pharmacology from the University of Zurich/ETH, and obtained an Executive MBA from the University of St. Gallen.
Roger is a seasoned early stage life sciences board member and assisted numerous start-up and growth companies and projects in their set-up, talent and fund sourcing. He is the founder and owner of Clarena Ltd., a company that serves corporates and executives in the fields of corporate finance, change management, coaching and HR. In his earlier career, he consulted mid to large sized multinational companies at Coopers & Lybrand (later PwC) in the field of financial and risk management. In the 80´s, he helped the US investment bank Salomon Brothers Inc., in the US, UK and Switzerland to establish a Swiss client base with institutional investors.
Before he worked as a trader with a Geneva private bank and in Private Banking at Swiss Bank Corp in Basel. In the past years, Roger has been involved in companies like Piqur Therapeutics, Strekin, Cellestia Biotech and many others as advisor and/or co-founder. He holds a finance degree from the University of Applied Sciences in Basel.